| abstract |
A pharmaceutical preparation for prophylaxis against and treatment of Staphylococcus induced infections or condi-tions in humans and animals, is disclosed, wherein it comprises a combination of a) one or more viable α-Streptococcus strains chosen from the group consisting of the Streptococcus sanguis JI strains having the accession numbers NCTMB 40104, NCTMB 40105, NCIMB 40106, and NCIMB 40873, the Streptococcus mitis strains having the accession numbers NCIMB 40107, and NCIMB 40874, the Streptococcus oralis strains having the accession numbers NCIMB 40875 and NCIMB 40876, the Streptococcus lactis strain LIA having the accession number NCIMB 40157, and one or more variants thereof having the same or essentially similar effect; and b) one or more viable Lactobacillus strains chosen from the group consisting of the Lactobacillus rhamnosus strain LB2 I having the accession number NCIMB 40564, the Lactobacillus plantamm strain LB3 having the accession number DSM 17852, and the Lactobacillus plantarwn strain LB7 having the accession number DSM 1 7853, and one or more variants thereof having the same or essentially similar effect; in at least one pharmaceutically acceptable medium in which said strains maintain their viability, as well as a kit for and a method of prophylaxis and treatment of Staphylococcus induced infections and conditions, and use. |